The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma

Oncology

Volumn 68, Issue 2-3, 2005, Pages 196-203

  Kuvaja, Paula ^a   Talvensaari Mattila, Anne ^a   Pääkkö, Paavo ^a   Turpeenniemi Hujanen, Taina ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast cancer; Invasion; Metastasis; Survival; TIMPs

Indexed keywords

AVIDIN; BIOTIN; PARAFFIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; STAINING; SURVIVAL; TISSUE SECTION; TUMOR GROWTH; BREAST TUMOR; CARCINOMA; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION REGULATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 15244339896     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086774     Document Type: Article

References (27)

1. Tryggvason K, Höyhtyä M, Pyke C: Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-218.
2. Chambers AF, Matrisian LM: Changing view of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
3. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 2000;18:1135-1149.
4. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 1998;83:1153-1162.
5. Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T: Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003;89:1270-1275.
6. 0 breast carcinoma. Breast Cancer Res Treat 2003;77:85-91.
7. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): Structure, control of expression and biological functions. Pharmacol Ther 1993;59:329-341.
8. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-122.
9. Hayakawa T, Yamashita K, Kishi J, Harigaya K: Tissue inhibitor of metalloproteinases from human bone marrow stromal cell line KM 102 has erythroid-potentiating activity, suggesting its possible bifunctional role in the hematopoietic microenvironment. FEBS Lett 1990;268:125-128.
10. Stetler-Stevenson WG, Bersch N, Golde DW: Tissue inhibitor of metalloproteinase 2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett 1992;296:231-234.
11. Hermanek P, Sobin LH (eds): UICC TNM Classification of Malignant Tumours, ed 4, rev 2. Berlin, Springer-Verlag, 1992.
12. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 1957.
13. Kallakury BVS, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001;7:3113-3119.
14. Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatis J, Keramopoulos A: Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol 2002;15:26-34.
15. Ross JS, Kaur P, Sheehan CE, Hugh BS, Fisher AG, Kaufman RA Jr, Kallakury BVS: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol 2003;16:198-205.
16. Visscher DW, Höyhtyä M, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Fridman R: Enhanced expression on tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. Int J Cancer 1994;59:339-344.
17. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S, Davaris P: Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002;197:307-313.
18. Höyhtyä M, Fridman R, Komarek D, Porter-Jordan K, Stetler-Stevenson WG, Liotta LA, Liang CM: Immunohistochemical localization of matrix metalloproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994;56:500-505.
19. Hansen Ree A, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O: High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997;3:1623-1628.
20. Brummer O, Athar S, Riethdorf L, Loning T, Herbst H: Matrix metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in beningn and malignant breast lesions: An in situ hybridization study. Virchows Arch 1999;435:566-573.
21. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ: High levels of tissue inhibitors of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999;884:44-48.
22. Ylisirniö S, Höyhtyä M, Turpeenniemi-Hujanen T: Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 2000;20:1311-1316.
23. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, Brunner N, Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999;80:495-503.
24. Luparello C, Avanzato G, Carella C, Pucci-Minafra I: Tissue inhibitor of metalloproteinase (TIMP-1) and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-244.
25. Inoue H, Mimore K, Shiraishi T, Kataoka A, Sadanaga N, Ueo H, Barnard GF, More M: Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol Rep 2000;7:871-874.
26. Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H: Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model. Int J Cancer 2003;105:340-346.
27. Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ: High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000;89:118-121.